We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Marketing Home Genomics Tests Should Be Undertaken with Caution

By Labmedica staff writers
Posted on 27 Mar 2008
More than two-dozen companies have been marketing a range of genetic tests directly to consumers concerned about genetic conditions. More...
These conditions include those related to risks for disease, other genetic traits, and ancestry. Some of these companies have marketed "whole genome scans,” which provide assessments of risk for various health conditions ranging from the type of earwax an individual forms to a risk for disease, including cancer, diabetes, and blindness.

According to Dr. Kenneth Offit, M.D., M.P.H., chief of the Clinical Genetics Service at Memorial Sloan-Kettering Cancer Center (MSKCC; New York, NY, USA), marketing of "at home” genomic tests for disease risk may be premature. "Health professionals are now faced with the prospect of their patients coming to the office, a DNA profile in hand, asking for preventative management tailored to their specific disease risks,” Dr. Offit wrote in the March 19, 2008 special genomics issue of the Journal of the American Medical Association (JAMA).

Dr Offit is concerned about the scientific accuracy of some of these tests, because "they have not yet been validated in forward looking [prospective] clinical studies.” In addition, he wrote, the laboratory accuracy of these tests may vary. A second concern voiced in the commentary is the "direct to consumer” aspect of the marketing of these tests, which excludes guidance from healthcare professionals.

The JAMA article reminds readers that certain state health departments, including New York's, have indicated that genetic testing for disease risk must be requested by a licensed healthcare professional and must be performed in an approved clinical laboratory.

As one of the leaders of the clinical introduction of genetic testing for breast and colon cancer over the past decade, Dr. Offit is in favor of the cautious introduction of new "whole genome” testing, preferably in the setting of ongoing clinical trials. "Those of us in the field of genetic testing for cancer risk proceeded cautiously…The same approach should be followed for genomic testing for other disease risks” he said. "Not doing so runs the risk of dangerously reassuring some and needlessly worrying the already worried [as] well.”


Related Links:
Memorial Sloan-Kettering Cancer Center

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.